Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
2006 International Conference on Biomedical and Pharmaceutical Engineering
| 2006 International Conference on Biomedical and Pharmaceutical Engineering |
| Pubbl/distr/stampa | Singapore, : Research Publishing |
| Soggetto topico |
Biomedical engineering
Pharmaceutical technology Pharmaceutical biotechnology Drugs - Design |
| ISBN |
9788190426244
81-904262-1-4 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910873003203321 |
| Singapore, : Research Publishing | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
AAPS open
| AAPS open |
| Pubbl/distr/stampa | London, United Kingdom : , : Springer, , [2015]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Pharmaceutical technology
Drugs - Design Farmacologia Revistes electròniques Pharmaceutical Preparations Drug Design Techniques pharmaceutiques Médicaments - Conception Médicaments |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 2364-9534 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | American Association of Pharmaceutical Scientists open |
| Record Nr. | UNINA-9910137216903321 |
| London, United Kingdom : , : Springer, , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
AAPS open
| AAPS open |
| Pubbl/distr/stampa | London, United Kingdom : , : Springer, , [2015]- |
| Descrizione fisica | 1 online resource |
| Soggetto topico |
Pharmaceutical technology
Drugs - Design Farmacologia Revistes electròniques Pharmaceutical Preparations Drug Design Techniques pharmaceutiques Médicaments - Conception Médicaments |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 2364-9534 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | American Association of Pharmaceutical Scientists open |
| Record Nr. | UNISA-996217618803316 |
| London, United Kingdom : , : Springer, , [2015]- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef
| Absorption and drug development : solubility, permeability, and charge state / / Alex Avdeef |
| Autore | Avdeef Alex |
| Edizione | [2nd ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2012 |
| Descrizione fisica | 1 online resource (742 p.) |
| Disciplina | 615/.19 |
| Soggetto topico |
Drugs - Design
Drugs - Metabolism Drug development Absorption |
| ISBN |
1-62198-226-2
1-280-58934-5 9786613619174 1-118-28603-0 1-118-28606-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction -- Transport model -- pKa determination -- Octanol-water partitioning -- Liposome-water partitioning -- Solubility -- Permeability - Pampa -- Permeability Caco 2/MDCK -- Permeability blood brain barrier. |
| Record Nr. | UNINA-9910141449403321 |
Avdeef Alex
|
||
| Hoboken, N.J., : John Wiley & Sons, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ACS combinatorial science
| ACS combinatorial science |
| Pubbl/distr/stampa | Washington, DC, : American Chemical Society, [2011]-[2020] |
| Descrizione fisica | 1 online resouce |
| Disciplina | 543 |
| Soggetto topico |
Combinatorial chemistry
QSAR (Biochemistry) Drugs - Design |
| Soggetto genere / forma | Periodicals. |
| ISSN | 2156-8944 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti |
American Chemical Society combinatorial science
Combinatorial science ACS comb. sci |
| Record Nr. | UNINA-9910138754803321 |
| Washington, DC, : American Chemical Society, [2011]-[2020] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME Processes in Pharmaceutical Sciences : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga
| ADME Processes in Pharmaceutical Sciences : Dosage, Design, and Pharmacotherapy / / edited by Alan Talevi, Pablo A. Quiroga |
| Autore | Talevi Alan |
| Edizione | [2nd ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (489 pages) |
| Disciplina | 615.19 |
| Altri autori (Persone) | QuirogaPablo A |
| Soggetto topico |
Pharmaceutical chemistry
Pharmacology Toxicology Pharmacy Drugs - Design Pharmaceutics Structure-Based Drug Design |
| ISBN | 3-031-50419-4 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1: The basics of ADME processes -- Chapter 1-Introduction. Biopharmaceutics and Pharmacokinetics -- Chapter 2-Drug release -- Chapter 3-Drug Absorption -- Chapter 4-Drug Distribution -- Chapter 5-Drug Metabolism -- Chapter 6-Drug Excretion -- Chapter 7-Drug Delivery Routes -- Chapter 8-Compartmental Pharmacokinetic Models -- Chapter 9-Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models -- Chapter 10-Drug Drug and Food Drug Interactions of Pharmacokinetic Nature -- Part 2: Specialized topics -- Chapter 11-Nanocarriers: Delivery Routes -- Chapter 12-Advanced Techniques for Quality Assessment of Nanocarriers -- Chapter 13-Nanomedicines Obtained by Nanoprinting -- Chapter 14-Absorption, Distribution, Metabolism and Excretion of Biopharmaceutical Drug Products -- Chapter 15-In silico and in vitro ADME predictions -- Chapter 16-Relationship Between Pharmacokinetics and Pharmacogenomics and Its Impact on Drug Choice and Dose Regimens -- Chapter 17-The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics -- Chapter 18-Bioavailability and Bioequivalence studies -- Chapter 19-Drug transporters – Physiological role and Their Impact on Pharmacotherapy -- Chapter 20-Blood Flow Distribution and Membrane Transporters As Determinant Factors Of Tissue Drug Concentration. |
| Record Nr. | UNINA-9910847085703321 |
|
Talevi Alan
|
||
| Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development [[electronic resource] /] / edited by Donglu Zhang, Sekhar Surapaneni |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910141254203321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni
| ADME-enabling technologies for drug design and development / / edited by Donglu Zhang, Sekhar Surapaneni |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley, c2012 |
| Descrizione fisica | 1 online resource (623 p.) |
| Disciplina | 615.1/9 |
| Altri autori (Persone) |
ZhangDonglu
SurapaneniSekhar |
| Soggetto topico |
Drugs - Design
Drug development Drugs - Metabolism Pharmaceutical chemistry Pharmacokinetics Pharmaceutical technology |
| ISBN |
1-280-59257-5
9786613622402 1-118-18076-3 1-118-18077-1 1-118-18074-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADME-Enabling Technologies in Drug Design and Development; CONTENTS; FOREWORD; PREFACE; CONTRIBUTORS; PART A: ADME: OVERVIEW AND CURRENT TOPICS; 1: REGULATORY DRUG DISPOSITION AND NDA PACKAGE INCLUDING MIST; 1.1 INTRODUCTION; 1.2 NONCLINICAL OVERVIEW; 1.3 PK; 1.4 ABSORPTION; 1.5 DISTRIBUTION; 1.5.1 Plasma Protein Binding; 1.5.2 Tissue Distribution; 1.5.3 Lacteal and Placental Distribution Studies; 1.6 METABOLISM; 1.6.1 In vitro Metabolism Studies; 1.6.2 Drug-Drug Interaction Studies; 1.6.3 In vivo Metabolism (ADME) Studies; 1.7 EXCRETION; 1.8 IMPACT OF METABOLISM INFORMATION ON LABELING
1.9 CONCLUSIONSREFERENCES; 2: OPTIMAL ADME PROPERTIES FOR CLINICAL CANDIDATE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.1 INTRODUCTION; 2.2 NCE AND INVESTIGATIONAL NEW DRUG (IND) PACKAGE; 2.3 ADME OPTIMIZATION; 2.3.1 Absorption; 2.3.2 Metabolism; 2.3.3 PK; 2.4 ADME OPTIMIZATION FOR CNS DRUGS; 2.5 SUMMARY; REFERENCES; 3: DRUG TRANSPORTERS IN DRUG INTERACTIONS AND DISPOSITION; 3.1 INTRODUCTION; 3.2 ABC TRANSPORTERS; 3.2.1 Pgp (MDR1, ABCB1); 3.2.2 BCRP (ABCG2); 3.2.3 MRP2 (ABCC2); 3.3 SLC TRANSPORTERS; 3.3.1 OCT1 (SLC22A1) and OCT2 (SLC22A2); 3.3.2 MATE1 (SLC47A1) and MATE2K (SLC47A2) 3.3.3 OAT1 (SLC22A6) and OAT3 (SLC22A8)3.3.4 OATP1B1 (SLCO1B1, SLC21A6), OATP1B3 (SLCO1B3, SLC21A8), and OATP2B1 (SLCO2B1, SLC21A9); 3.4 IN VITRO ASSAYS IN DRUG DEVELOPMENT; 3.4.1 Considerations for Assessing Candidate Drugs as Inhibitors; 3.4.2 Considerations for Assessing Candidate Drugs as Substrates; 3.4.3 Assay Systems; 3.5 CONCLUSIONS AND PERSPECTIVES; REFERENCES; 4: PHARMACOLOGICAL AND TOXICOLOGICAL ACTIVITY OF DRUG METABOLITES; 4.1 INTRODUCTION; 4.2 ASSESSMENT OF POTENTIAL FOR ACTIVE METABOLITES; 4.2.1 Detection of Active Metabolites during Drug Discovery 4.2.2 Methods for Assessing and Evaluating the Biological Activity of Metabolite Mixtures4.2.3 Methods for Generation of Metabolites; 4.3 ASSESSMENT OF THE POTENTIAL TOXICOLOGY OF METABOLITES; 4.3.1 Methods to Study the Formation of Reactive Metabolites; 4.3.2 Reactive Metabolite Studies: In vitro; 4.3.3 Reactive Metabolite Studies: In vivo; 4.3.4 Reactive Metabolite Data Interpretation; 4.3.5 Metabolite Contribution to Off-Target Toxicities; 4.4 SAFETY TESTING OF DRUG METABOLITES; 4.5 SUMMARY; REFERENCES 5: IMPROVING THE PHARMACEUTICAL PROPERTIES OF BIOLOGICS IN DRUG DISCOVERY: UNIQUE CHALLENGES AND ENABLING SOLUTIONS5.1 INTRODUCTION; 5.2 PHARMACOKINETICS; 5.3 METABOLISM AND DISPOSITION; 5.4 IMMUNOGENICITY; 5.5 TOXICITY AND PRECLINICAL ASSESSMENT; 5.6 COMPARABILITY; 5.7 CONCLUSIONS; REFERENCES; 6: CLINICAL DOSE ESTIMATION USING PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION; 6.1 INTRODUCTION; 6.2 BIOMARKERS IN PK AND PD; 6.2.1 PK; 6.2.2 PD; 6.2.3 Biomarkers; 6.3 MODEL-BASED CLINICAL DRUG DEVELOPMENT; 6.3.1 Modeling; 6.3.2 Simulation; 6.3.3 Population Modeling 6.3.4 Quantitative Pharmacology (QP) and Pharmacometrics |
| Record Nr. | UNINA-9910816078003321 |
| Hoboken, N.J., : Wiley, c2012 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
ADMET for medicinal chemists : a practical guide / / edited by Katya Tsaioun, Steven A. Kates
| ADMET for medicinal chemists : a practical guide / / edited by Katya Tsaioun, Steven A. Kates |
| Pubbl/distr/stampa | Hoboken, N.J., : John Wiley & Sons, c2011 |
| Descrizione fisica | 1 online resource (524 p.) |
| Disciplina |
615.19
615/.19 |
| Altri autori (Persone) |
KatesSteven A. <1961->
TsaiounKatya |
| Soggetto topico |
Drugs - Testing
Drugs - Design |
| ISBN |
1-280-59122-6
9786613621054 0-470-91509-9 0-470-91511-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ADMET for Medicinal Chemists: A Practical Guide; CONTENTS; Preface; Contributors; 1 Introduction; 1.1 Introduction; 1.2 Voyage Through The Digestive System; 1.2.1 The Mouth; 1.2.2 The Stomach; 1.2.3 The Small Intestine: Duodenum; 1.2.4 The Small and Large Intestine: Jejunum, Ileum, Colon; 1.2.5 Hepatic-Portal Vein; 1.3 The Liver Metabolism; 1.3.1 CYP450 (CYPs); 1.4 The Kidneys; 1.4.1 Active Tubular Secretion; 1.4.2 Passive Tubular Reabsorption; 1.5 Conclusions; References; 2 In Silico ADME/Tox Predictions; 2.1 Introduction; 2.2 Key Computer Methods for ADME/Tox Predictions
2.2.1 Drug Discovery2.2.2 Applying or Not ADME/Tox Predictions, Divided Opinions; 2.2.3 In Silico ADME/Tox Methods and Modeling Approaches; 2.2.4 Physicochemistry, Pharmacokinetics, Drug-Like and Lead-Like Concepts; 2.2.5 Lipophilicity; 2.2.6 pKa; 2.2.7 Transport Proteins; 2.2.8 Plasma Protein Binding; 2.2.9 Metabolism; 2.2.10 Elimination; 2.2.11 Toxicity; 2.3 Preparation of Compound Collections and Computer Programs, Challenging ADME/Tox Predictions and Statistical Methods; 2.3.1 Preparation of Compound Collections and Computer Programs 2.3.2 Preparing a Compound Collection: Materials and Methods2.3.3 Cleaning and Designing the Compound Collection; 2.3.4 Searching for Similarity; 2.3.5 Generating 3D Structures; 2.4 ADME/Tox Predictions within Pharmaceutics Companies; 2.4.1 Actelion Pharmaceuticals Ltd.; 2.4.2 Bayer; 2.4.3 Bristol-Myers Squibb; 2.4.4 Hoffmann-La Roche Ltd.; 2.4.5 Neurogen Corporation; 2.4.6 Novartis; 2.4.7 Schering AG; 2.4.8 Vertex Pharmaceuticals; 2.5 Challenging ADME/Tox Predictions; 2.5.1 Tolcapone; 2.5.2 Factor V Inhibitors; 2.5.3 CRF-1 Receptor Antagonists; 2.6 Statistical Methods 2.6.1 Principal Component Analysis2.6.2 Partial Least Square; 2.6.3 Support Vector Machine; 2.6.4 Decision Trees; 2.6.5 Neural Networks; 2.7 Conclusions; References; 3 Absorption and Physicochemical Properties of the NCE; 3.1. Introduction; 3.2. Physicochemical Properties; 3.3. Stability; 3.4. Dissolution and Solubility; 3.4.1. Dissolution Rate, Particle Size, and Solubility; 3.4.2. pH and Salts; 3.4.3. In Vivo Solubilization; 3.5. Solid State; References; 4 ADME; 4.1 Introduction; 4.2 Absorption; 4.2.1 Route of Administration; 4.2.2 Factors Determining Oral Bioavailability; 4.3 Distribution 4.3.1 Drug Distribution4.3.2 Volume of Distribution; 4.3.3 Free Drug Concentration; 4.3.4 CNS Penetration; 4.4 Elimination; 4.4.1 Elimination Versus Clearance; 4.4.2 Metabolism Versus Excretion; 4.4.3 Drug-Free Fraction and Clearance; 4.4.4 Lipophilicity and Clearance; 4.4.5 Transporters and Clearance; 4.4.6 Metabolism; 4.4.7 Excretion; 4.5 Drug Interactions; 4.5.1 Absorption-Driven DDI; 4.5.2 Distribution-Driven DDI; 4.5.3 Excretion-Driven DDI; 4.5.4 Metabolism-Driven DDI; 4.5.5 Tools for Studying Drug Metabolism; 4.5.6 Applications of Drug Metabolism Tools 4.5.7 Tools for Studying Drug Excretion |
| Altri titoli varianti | Absorption, distribution, metabolism, excretion, toxicity for medical chemists |
| Record Nr. | UNINA-9910876861103321 |
| Hoboken, N.J., : John Wiley & Sons, c2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Adrenoceptors / / edited by Jillian G. Baker, Martin C. Michel, Roger J. Summers
| Adrenoceptors / / edited by Jillian G. Baker, Martin C. Michel, Roger J. Summers |
| Autore | Baker Jillian G |
| Edizione | [1st ed. 2024.] |
| Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 |
| Descrizione fisica | 1 online resource (691 pages) |
| Disciplina | 615 |
| Altri autori (Persone) |
MichelMartin C
SummersRoger J |
| Collana | Handbook of Experimental Pharmacology |
| Soggetto topico |
Pharmacology
Drugs - Design Structure-Based Drug Design |
| ISBN | 3-031-66776-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Introduction: a short history of adrenoceptor research -- Structures of Adrenoceptors -- Genetic Variants of Adrenoceptors -- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays -- Signalling of adrenoceptors: canonical pathways and new paradigms -- Presynaptic Adrenoceptors -- Roles of b-adrenoceptor subtypes and therapeutics in human cardiovascular disease:- heart failure, tachyarrhythmias and other cardiovascular disorders -- Adrenoceptors and Hypertension -- Adrenoceptors in the Lower Urinary Tract -- Asthma and COPD: A Focus on b-Agonists – Past, Present and Future -- Adrenoceptors in the Eye- Physiological and Pathophysiological Relevance -- Adrenoceptors: A Focus on Psychiatric Disorders and Their Treatments -- Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease -- Clinical use of adrenergic receptor ligands in acute care settings -- Adrenoceptor expression and function in the endocrine pancreas -- b-adrenoceptors in cancer: old players and new perspectives. |
| Record Nr. | UNINA-9910886988303321 |
|
Baker Jillian G
|
||
| Cham : , : Springer International Publishing : , : Imprint : Springer, , 2024 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Drugs - Design
(318)
- Pharmaceutical chemistry (94)
- Drug development (69)
- Drug Design (37)
- Pharmacology (20)